Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee (April 2024) aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters.
GCS will establish and grow its research facilities in the Dundee area. The scientific team continues to grow so if you aspire not only to be at the core of biotech innovation but also to tackle the global problem of high-cost medicine, get in touch.